Acute Disseminated Encephalomyelitis Presenting With Paraplegia and a Neurogenic Bladder: A Case Report and Brief Literature Review Authors: Laura Longo, Giuseppina Bonfiglio, Rossella Longo Published: 2026 ABSTRACT Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated demyelinating disorder in children. While lower urinary tract dysfunction (LUTD) is estimated to affect up to 33% of patients, it is frequently overlooked in clinical reports, and specific rehabilitation strategies are still lacking. We describe a pediatric patient with ADEM presenting with paraplegia and an areflexic neurogenic bladder, managed with a structured rehabilitation protocol, including clean intermittent catheterization, afferent neuromodulation, and pelvic floor training. Progressive neurological and urinary recovery was achieved within 2 months. This case highlights the potential role of early multidisciplinary rehabilitation in promoting bladder recovery in ADEM. Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disorder of the central nervous system, predominantly affecting children, and is characterized by encephalopathy and multifocal neurological deficits.1,2 Its incidence is estimated at 0.4-0.8 per 100,000 individuals per year, with a strong pediatric predominance.1,3 Although ADEM typically presents with motor, sensory, and cognitive disturbances, autonomic dysfunction, particularly lower urinary tract dysfunction (LUTD), is significantly less emphasized in the literature than motor and sensory disturbances, despite its prevalence. The earliest and most detailed description of urinary dysfunction in ADEM dates back to Sakakibara et al,4 who reported abnormalities such as detrusor areflexia and detrusor-sphincter dyssynergia. Later studies by Panicker et al confirmed that urinary retention may occur during the acute phase of ADEM. However, the literature remains limited to acute management, typically catheterization, and provides no guidance on rehabilitation protocols or long-term urological outcomes. This lack of evidence is problematic because prolonged retention may lead to recurrent infections, vesicoureteral reflux, and renal impairment. Furthermore, children with ADEM usually have a favorable motor prognosis,5,6 making bladder rehabilitation a meaningful therapeutic target. This work includes a detailed case report of a neurogenic bladder due to ADEM in a pediatric patient, managed with a structured rehabilitation protocol, followed by a brief synthesis of the literature on LUTD in ADEM, highlighting its prevalence (up to 33%) and the current lack of evidence for rehabilitation. Finally, the clinical implications and potential generalizability of this approach are discussed. This report follows the Introduction, Methods, Results, and Discussion (IMRaD) structure and the CAse REport (CARE) guidelines. Methods Study design This was a single-patient clinical case report with retrospective and prospective data collection, structured according to the IMRaD guidelines. A focused literature review was conducted to summarize existing knowledge of neurogenic bladder in ADEM. Data collection Clinical data were obtained from several sources, including electronic medical records, neurological examinations, urodynamic testing, magnetic resonance imaging (MRI) findings, and rehabilitation notes from follow-up visits. Ethical considerations Written informed consent was obtained from the patient’s legal guardian for the publication of this case report and any accompanying images. Ethical approval was not required for this case report in accordance with local/national guidelines. Literature review procedures To contextualize the reported prevalence of bladder involvement in ADEM, PubMed and Scopus were searched using the terms “ADEM,” “neurogenic bladder,” “urinary retention,” and “LUTD,” and only English-language clinical studies describing urinary symptoms in patients with ADEM were included. The search confirmed the rarity of the condition and identified 3 relevant case reports that specifically described urinary symptoms,7, 8, 9 all of which focused solely on acute management. Broader reviews of ADEM diagnosis and treatment were also considered.1,5,10,11 Results Case presentation A 12-year-old previously healthy boy presented with rapid-onset lower-limb weakness over 3 days, which progressed to paraplegia and acute urinary retention. A week before symptom onset, the boy received a second dose of the human papillomavirus vaccine. Neurologic examination revealed muscle strength of 0/5 bilaterally in the lower limbs, accompanied by sacral hypoesthesia (S2-S4), an absent cremasteric reflex, and decreased anal tone. The patient underwent a lumbar puncture, which revealed no pleocytosis or cellular dysmorphism in the cerebrospinal fluid (CSF). Diffusion-weighted imaging (DWI) was nondiagnostic for these assessments. Electroencephalography findings were within normal limits. Oligoclonal bands were present, with partial involvement of the spinal cord and the periventricular regions of the brain. Investigations Lumbar puncture CSF analysis showed a clear appearance, with a cell count of 75 cells/µL (33.3% mononuclear and 6.7% polymorphonuclear), a protein level of 72 mg/dL, and a glucose level of 49 mg/dL. Further biochemical analysis revealed an albumin level of 39.7 g/L, a CSF/serum albumin ratio of 11.21, and a CSF/serum glucose ratio of 0.54. Immunological markers included a CSF immunoglobulin (Ig)G/albumin ratio of 0.22, a Link Index of 0.69, indicating intrathecal IgG synthesis, and CSF free kappa chains of 0.75. Notably, 7 oligoclonal bands were found, matching those in the serum, alongside cytomegalovirus (CMV) and human herpesvirus (HHV)cytomegalovirus (CMV) and positivity (7), which also corresponded to serum findings (table 1).Table 1CSF and serum laboratory findings.Table 1 dummy alt textParameterValueAppearanceClearCell count, cells/µL75 (mononuclear: 33.3%; polymorphonuclear: 6.7%)Proteins, mg/dL72Glucose, mg/dL49CSF/serum albumin ratio11.21CSF/serum glucose ratio0.54CSF IgG/albumin ratio0.22Link Index (intrathecal IgG)0.69CSF free kappa chains0.75Oligoclonal bands7 (matched in serum)Viral screening (HHV, CMV)Positive (matched in serum)Abbreviations: CMV, citomegalovirus; HHV, human herpesvirus. Table 1CSF and serum laboratory findings.Table 1 dummy alt textParameterValueAppearanceClearCell count, cells/µL75 (mononuclear: 33.3%; polymorphonuclear: 6.7%)Proteins, mg/dL72Glucose, mg/dL49CSF/serum albumin ratio11.21CSF/serum glucose ratio0.54CSF IgG/albumin ratio0.22Link Index (intrathecal IgG)0.69CSF free kappa chains0.75Oligoclonal bands7 (matched in serum)Viral screening (HHV, CMV)Positive (matched in serum)Abbreviations: CMV, citomegalovirus; HHV, human herpesvirus. CSF and serum laboratory findings. Abbreviations: CMV, citomegalovirus; HHV, human herpesvirus. Serologic antibodies The comprehensive immunological screening was negative for antineuronal, antiencephalitis, anti aquaporin-4 (AQP4) and anti myelin oligodendrocyte glycoprotein (MOG) antibodies. Serological testing for Chlamydia, cytomegalovirus (CMV), and Rubella (IgM) was also negative. However, results were positive for Mycoplasma pneumoniae IgG (1:160), indicating previous exposure to Epstein-Barr virus (Epstein-Barr nuclear antigen IgG>600, viral capsid antigen IgG 1:341) and Rubella (IgG 1:341). Autoantibody screening revealed an antinuclear antibody titer of 1:320, while antimitochondrial antibody and anti-smooth muscle antibody were negative; serum-free kappa chains were 0.69 mg/dL (table 2).Table 2Serum antibody and serological profile.Table 2 dummy alt textCategoryParameterResultsNeural antibodiesAntineuronal (Hu, MAG, myelin, Ri, Yo, GAD)NegativeAntiencephalitis (NMDA, CASPR2, LGI1, CNTN-1)NegativeAnti-AQP4 and Anti-MOGNegativeInfectious serologyMycoplasma pneumoniae IgGPositive (1:160)Chlamydia (pneumoniae/trachomatis) IgA/IgGNegativeEBV (EBNA IgG/VCA IgG)Positive (>600/1:341)Rubella (IgG/IgM)Positive (1:341)/negativeCMV (IgG/IgM)NegativeAutoimmunityANAPositive (1:320)AMA, ASMANegativeSerum-free kappa chains0.69Abbreviations: ANA, antinuclear antibody; Hu, Anti-Hu antibody (also known as ANNA-1, Anti-Neuronal Nuclear Antibody Type 1); MAG, myelin-associated glycoprotein; Ri, anti-Ri antibody (also known as ANNA-2, Anti-Neuronal Nuclear Antibody Type 2); Yo, Anti-Yo antibody (also known as PCA-1, Purkinje Cell Cytoplasmic Antibody Type 1); GAD, glutamic acid decarboxylase; NMDA, N-methyl-D-aspartate (typically referring to the NMDA receptor / NMDAR); CASPR2, contactin-associated protein-like 2; LGI1, leucine-rich glioma-inactivated 1; CNTN-1, contactin-1; AQP4, aquaporin-4; EBV, epstein-barr virus; EBNA, epstein-barr nuclear antigen; VCA, viral capsid antigen (associated with EBV); CMV, cytomegalovirus; AMA, antimitochondrial antibody; ASMA, anti-smooth muscle antibody. Table 2Serum antibody and serological profile.Table 2 dummy alt textCategoryParameterResultsNeural antibodiesAntineuronal (Hu, MAG, myelin, Ri, Yo, GAD)NegativeAntiencephalitis (NMDA, CASPR2, LGI1, CNTN-1)NegativeAnti-AQP4 and Anti-MOGNegativeInfectious serologyMycoplasma pneumoniae IgGPositive (1:160)Chlamydia (pneumoniae/trachomatis) IgA/IgGNegativeEBV (EBNA IgG/VCA IgG)Positive (>600/1:341)Rubella (IgG/IgM)Positive (1:341)/negativeCMV (IgG/IgM)NegativeAutoimmunityANAPositive (1:320)AMA, ASMANegativeSerum-free kappa chains0.69Abbreviations: ANA, antinuclear antibody; Hu, Anti-Hu antibody (also known as ANNA-1, Anti-Neuronal Nuclear Antibody Type 1); MAG, myelin-associated glycoprotein; Ri, anti-Ri antibody (also known as ANNA-2, Anti-Neuronal Nuclear Antibody Type 2); Yo, Anti-Yo antibody (also known as PCA-1, Purkinje Cell Cytoplasmic Antibody Type 1); GAD, glutamic acid decarboxylase; NMDA, N-methyl-D-aspartate (typically referring to the NMDA receptor / NMDAR); CASPR2, contactin-associated protein-like 2; LGI1, leucine-rich glioma-inactivated 1; CNTN-1, contactin-1; AQP4, aquaporin-4; EBV, epstein-barr virus; EBNA, epstein-barr nuclear antigen; VCA, viral capsid antigen (associated with EBV); CMV, cytomegalovirus; AMA, antimitochondrial antibody; ASMA, anti-smooth muscle antibody. Serum antibody and serological profile. Abbreviations: ANA, antinuclear antibody; Hu, Anti-Hu antibody (also known as ANNA-1, Anti-Neuronal Nuclear Antibody Type 1); MAG, myelin-associated glycoprotein; Ri, anti-Ri antibody (also known as ANNA-2, Anti-Neuronal Nuclear Antibody Type 2); Yo, Anti-Yo antibody (also known as PCA-1, Purkinje Cell Cytoplasmic Antibody Type 1); GAD, glutamic acid decarboxylase; NMDA, N-methyl-D-aspartate (typically referring to the NMDA receptor / NMDAR); CASPR2, contactin-associated protein-like 2; LGI1, leucine-rich glioma-inactivated 1; CNTN-1, contactin-1; AQP4, aquaporin-4; EBV, epstein-barr virus; EBNA, epstein-barr nuclear antigen; VCA, viral capsid antigen (associated with EBV); CMV, cytomegalovirus; AMA, antimitochondrial antibody; ASMA, anti-smooth muscle antibody. MRI findings An urgent MRI of the brain, brainstem, and entire spinal cord (cervical, thoracic, and lumbosacral segments) was performed before and after gadolinium administration. The study was significantly limited by strong susceptibility artifacts from the patient’s fixed orthodontic appliances. Brain and spinal cord MRI revealed multifocal T2/fluid-attenuated inversion recovery (FLAIR) hyperintense lesions typical of ADEM,1,5,6,11 a presentation that has also been described after other vaccinations.10,12 Brain MRI identified several T2/FLAIR hyperintense lesions, specifically involving the left internal capsule and the right parieto-occipital subcortical white matter; additionally, focal hyperintensities were observed in the right fronto-parietal cortico-subcortical white matter. No pathological enhancement was observed after contrast administration. The DWI sequences were nondiagnostic due to artifacts. Spinal cord MRI demonstrated diffuse involvement of the central gray matter across multiple levels, with partial involvement of the thoracic white matter columns, and significant swelling of the thoracic spinal cord. These findings suggested an inflammatory demyelinating process, such as ADEM or MOG-associated disease, although an infectious etiology could not be entirely excluded. Further evaluation using CSF analysis and anti myelin oligodendrocyte glycoprotein (MOG)/ anti aquaporin-4 (AQP4) serology was recommended. Acute immunotherapy The patient was administered a corticosteroid bolus (methylprednisolone 1 g/d for 5 days). Concomitant antiviral therapy with acyclovir and antibiotic therapy with ceftriaxone were initiated. Neurourological evaluation: Urodynamic testing The urodynamic findings were consistent with detrusor areflexia, characterized by the absence of detrusor contraction and the total lack of both voluntary and reflex voiding. These patterns have previously been documented in ADEM.4 Urology initially recommended suprapubic catheterization; however, physiatry proposed an integrated rehabilitation program aimed at restoring bladder function in the patient. Rehabilitation intervention A structured 3-phase protocol was implemented, beginning with phase 1 (inpatient management), which focused on clean intermittent catheterization (CIC) as the criterion standard for neurogenic bladder dysfunction13 and on lower-limb motor rehabilitation to promote gait recovery. This was followed by phase 2 (early outpatient neuromodulation), during which the patient began receiving Stoller afferent nerve stimulation (SANS) twice weekly. This technique involves transcutaneous electrical stimulation of the posterior tibial nerve to activate pudendal afferent pathways, a method previously described for modulating micturition circuits in various neurogenic and nonneurogenic voiding dysfunctions.14, 15, 16, 17 The stimulation of these afferent pathways is hypothesized to influence the spinal and supraspinal centers that regulate bladder storage and emptying. By potentially facilitating neuroplastic changes in these neural circuits, SANS was used as a noninvasive adjunct to promote the recovery of bladder function in coordination with the patient’s overall neurological improvement. This neuromodulatory approach was selected as a conservative option for managing detrusor areflexia in the early stages of recovery. Finally, phase 3 (pelvic floor rehabilitation) was initiated as motor and sensory functions improved. This phase included pelvic floor muscle training (PFMT) focused on perineal sensory re-education, pubococcygeus strengthening, anal sphincter conditioning, and breathing/postural coordination. Given that PFMT has shown clinically significant benefits in neurogenic bladder secondary to multiple sclerosis, its application provided a strong rationale for this ADEM case.18 Clinical outcomes At discharge (20 days), the patient showed nearly complete motor recovery (5/5 in the right leg, 4/5 in the left leg), although CIC was still required and SANS was initiated. A follow-up MRI performed at this stage demonstrated marked radiologic improvement, with resolution of all cervical spinal cord signal changes, a reduction in thoracic lesions (now primarily involving T7-T10), and focal enlargement of the central canal. No contrast enhancement was observed in the spinal cord or the cauda equina roots. In the brain, the small left internal capsule hyperintensity remained unchanged, with no new lesions, and both leptomeningeal and pachymeningeal enhancements were absent. At the 1-month follow-up, the patient achieved full motor recovery and independent ambulation. Urological improvements included the first spontaneous voiding attempts using suprapubic tapping, a postvoid residual<50 mL, and bilateral return of the cremasteric reflex. By the 2-month follow-up, voiding was performed mostly via suprapubic tapping, reducing CIC to once nightly. Despite 2 episodes of fecal incontinence, which prompted an intensification of PFMT, the clinical course remained positive. A follow-up MRI (including Fast Spin-Echo, Turbo Spin-Echo , Diffusion-Weighted Imaging, T2-weighted angiography, 3-dimensional Fluid-Attenuated Inversion Recovery, and T1- and T2-weighted sequences) confirmed stable, subtle T2/FLAIR hyperintensities in the left nucleocapsular region and the right occipital white matter, with no new lesions. A whole-spine MRI (Turbo Spin-Echo, Short-Tau Inversion Recovery and T1- and T2-weighted sequences) showed that prior signal abnormalities were less evident, indicating progressive radiologic improvement and absence of new inflammatory activity, consistent with ADEM recovery. Discussion Clinical significance This report highlights a clinically meaningful yet often underreported manifestation of ADEM: neurogenic bladder due to detrusor areflexia. While some literature suggests that urinary dysfunction can affect up to 33% of patients with ADEM, specific rehabilitation strategies remain largely undescribed. Given the typical recovery potential of pediatric ADEM, long-term urinary dysfunction is not inevitable; however, without timely intervention, prolonged detrusor areflexia may lead to recurrent urinary tract infections, vesicoureteral reflux, renal impairment, and significant psychosocial consequences. A structured rehabilitation program offers a path to functional recovery by leveraging neural plasticity after acute demyelination, the recovery of sacral reflexes, and the progressive strengthening and coordination of pelvic musculature, all while ensuring safe bladder emptying via CIC. The rapid return of voiding sensation and reflex activity in our patient suggests that early neuromodulation may accelerate the recovery of sacral pathways. The potential for recovery is further highlighted by comparing pediatric outcomes with those of adult-onset ADEM. While both populations share an immune-mediated pathophysiology, adult-onset ADEM is frequently associated with more severe clinical presentations and a higher risk of progression to chronic disorders. According to the meta-analysis by Li et al,19 adults often exhibit a wide range of autonomic disturbances, with LUTD being a significant component of their clinical picture. However, a key distinction lies in regenerative capacity: children typically benefit from greater neural plasticity, as evidenced in this patient, whereas adults may require more prolonged and intensive rehabilitation due to lower recovery potential and higher disability scores at onset.19 Comparison with the literature Comprehensive studies focusing specifically on the management and long-term evolution of urinary dysfunction in ADEM remain limited. Only 3 recent case reports mentioned urinary retention in ADEM,7,8,20 and all of them described catheterization exclusively without rehabilitation or neuromodulation. Sakakibara et al4 described LUTD but offered no management recommendations, whereas Panicker et al reported only acute urodynamic abnormalities. These 3 case reports (2021-2024) described acute retention managed solely by catheterization.7,8,20 Consequently, this article presents the first reported structured rehabilitation approach for neurogenic bladder in ADEM. Generalizability Although this model is based on a single patient, it may be applicable to pediatric patients with ADEM and urinary retention, to those with ADEM and an areflexic bladder with preserved potential for neural recovery, and to clinical settings equipped for CIC training, neuromodulation, and pelvic rehabilitation. However, the generalizability of these findings is limited by the single-patient design, the natural recovery inherent in ADEM, variability in lesion distribution, and the potentially limited access to neuromodulation technologies in some centers. Future multicenter prospective studies are needed to establish evidence-based rehabilitation guidelines, which remain a common challenge in the management of rare neuroimmune disorders.13,21 Study limitations This is a single case study. Availability of neuromodulation may vary by center. Natural recovery in patients with ADEM may contribute to improvement. Conclusions Neurogenic bladder in ADEM is underrecognized and lacks rehabilitation guidelines. Only 3 published studies have described urinary retention in ADEM, all of which were limited to acute catheterization without rehabilitative intervention. This case report demonstrates that multidisciplinary rehabilitation, including CIC, afferent neuromodulation, and PFMT, may meaningfully improve bladder function and reduce the need for invasive procedures. This report serves as a clinically actionable model and highlights the urgent need for prospective research to inform the development of evidence-based guidelines. Author contributions All authors contributed to the conception, design, and writing of this manuscript. L.L. was responsible for data collection, initial drafting, and literature review. R.L. provided critical revisions and supervised the clinical management. L.L. performed the neurourological assessment and interpretation. All authors reviewed and approved the final version of the manuscript. Data statements The data that support the findings of this case report are available from the corresponding author upon reasonable request, in compliance with patient privacy and ethical standards. Disclosure The authors declare no conflicts of interest.